5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas

Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas

Mature B-cell neoplasms encompass a spectrum of clonal lymphoproliferative disorders originating from post-thymic, mature B-lymphocytes at various stages of differentiation (pre-germinal center, germinal center, or post-germinal center/memory cells). These disorders range from indolent, slowly progressive leukemias and lymphomas to aggressive, rapidly fatal malignancies.

---

1. Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in adults in Western countries, with a median age at diagnosis of 70 to 72 years and a 2:1 male-to-female predominance. CLL and Small Lymphocytic Lymphoma (SLL) are identical biologic and immunophenotypic entities; the designation CLL is applied when there is persistent absolute peripheral blood monoclonal lymphocytosis $\ge 5.0 \times 10^9/\text{L}$ ($5,000/\mu\text{L}$), whereas SLL is diagnosed when the disease is restricted to lymph nodes and spleen with $<5.0 \times 10^9/\text{L}$ circulating clonal B-cells.

                  CLL / SLL DIAGNOSTIC BIFURCATION
                                 │
     ┌───────────────────────────┴───────────────────────────┐
     ▼                                                       ▼
[ CHRONIC LYMPHOCYTIC LEUKEMIA ]            [ SMALL LYMPHOCYTIC LYMPHOMA ]
• Peripheral Blood Monoclonal B-Cells       • Nodal, Splenic, or Tissue Disease
  ≥ 5.0 × 10^9/L                            • Peripheral Clonal B-Cells < 5.0 × 10^9/L
• Bone Marrow Infiltration ≥30%             • Identical Morphology & Immunophenotype

Peripheral Blood Smear Morphology & The Smudge Cell Phenomenon

• Monotonous Lymphocytosis: The peripheral blood is dominated by small, mature-appearing lymphocytes with high nuclear-to-cytoplasmic (N:C) ratios, narrow rims of pale-blue agranular cytoplasm, and round nuclei with densely clumped, block-like chromatin classically described as having a "soccer-ball" or "cracked-mud" appearance. Nucleoli are absent or small and inconspicuous.
• Prolymphocytes: In typical CLL, prolymphocytes (larger cells with moderate cytoplasm and a prominent central vesicular nucleolus) comprise $<15%$ of circulating lymphoid cells. When prolymphocytes comprise $15\text{--}55%$, the disease is classified as CLL with increased prolymphocytes (CLL/PL); if $>55%$, it is classified as B-cell Prolymphocytic Leukemia (B-PLL), an aggressive disorder.
• Smudge Cells (Gumprecht Shadows / Basket Cells): Smudge cells are damaged, ruptured leukemic lymphocytes that appear as pale, pink-purple, structureless, smudged nuclear remnants on Romanowsky-stained smears. Because CLL lymphocytes have a defective vimentin-based cytoskeleton, they are exceptionally fragile and rupture under the mechanical shearing forces of spreading a blood drop on a glass slide.

                    THE ALBUMIN RECONSTITUTION TECHNIQUE

 Problem:  Excessive Smudge Cells Rupture on Routine Peripheral Smear
           └──► Inaccurate Automated & Manual WBC Differential Counts

 Solution: [ 1 Drop of 22% Bovine Serum Albumin ] + [ 4 - 5 Drops of EDTA Whole Blood ]
                                     │
                                     ▼
                 Mix Thoroughly & Prepare Manual Wedge Smear
                                     │
                                     ▼
               Albumin Increases Oncotic Support & Stabilizes
                     Fragile Leukemic Cytoskeletons
                                     │
                                     ▼
             Result: Intact Lymphocyte Morphology Restored for
                    Accurate 100-Cell Manual Differential

Laboratory Technique & Board Rule: Albumin Smear Preparation

When smudge cells are numerous on a routine peripheral blood film, they can prevent an accurate manual differential count.

• Protocol: Add 1 drop of 22% bovine serum albumin to 4 to 5 drops of EDTA-anticoagulated whole blood, mix gently, and prepare a new wedge smear.
• Effect: Albumin provides oncotic support and structural stabilization to the fragile cytoplasmic membranes, preventing cellular lysis during smearing while leaving cellular morphologic characteristics intact.
• Reporting Rule: The albumin-treated slide is used strictly for performing the manual differential count. The absolute WBC count, hemoglobin, hematocrit, and red cell/platelet morphologies must always be evaluated and reported from the original non-albumin EDTA blood sample.

Multiparameter Flow Cytometric Immunophenotype

Flow cytometry on peripheral blood or bone marrow is the definitive diagnostic modality for CLL. Malignant CLL cells display a distinctive immunophenotypic profile:

• Pan-B-Cell Markers: CD19+, CD20+ (characteristically DIM), CD22+ (dim), and CD79a+.
• Aberrant T-Cell Antigen Co-Expression: CD5+ (co-expressed aberrantly on the clonal B-cells).
• Key Positive Markers: CD23+ (bright), CD200+ (uniformly bright), and CD43+.
• Clonal Light Chain Restriction: Surface immunoglobulin (sIg) is characteristically DIM, showing monoclonal restriction to either $\kappa$ (kappa) dim or $\lambda$ (lambda) dim.
• Key Negative Markers: CD10 NEGATIVE, Cyclin D1 NEGATIVE, FMC-7 NEGATIVE (or dim), and CD103 NEGATIVE.

                              FLOW CYTOMETRY GATING IN CLL

 CD5 (T-cell Marker) ──►  ▲
                          │   ┌───────────────────────────┐
                          │   │   CLASSIC CLL PHENOTYPE   │
                          │   │ • CD19+ / CD5+ / CD23+    │
                          │   │ • CD200+ (Bright)         │
                          │   │ • CD20 (Dim) / sIg (Dim)  │
                          │   │ • CD10- / Cyclin D1-      │
                          │   └───────────────────────────┘
                          │
                          └─────────────────────────────────────►
                                 CD19 (B-cell Marker)

Clinical Staging Systems (Rai and Binet)

Cytogenetic & Molecular Prognostic Markers

• Favorable Prognosis:
  • del(13q14) (as a sole abnormality): Deletion of the miR-15a/16-1 cluster; seen in $>50%$ of patients; associated with indolent disease and longest survival.
  • Mutated $IGHV$: $\ge 2%$ somatic hypermutation of the Immunoglobulin Heavy Chain Variable region gene compared to germline sequence, indicating origin from a post-germinal center memory B-cell (associated with durable response and prolonged survival).
• Unfavorable / Adverse Prognosis:
  • del(17p13) / $TP53$ Mutation: Deletion of the TP53 locus or somatic mutation of $TP53$; confers primary resistance to standard alkylating/purine chemoimmunotherapy. Patients require targeted therapies (BTK inhibitors [Ibrutinib, Acalabrutinib, Zanubrutinib] or BCL2 inhibitors [Venetoclax]).
  • del(11q22-23) / $ATM$ Mutation: Deletion involving the Ataxia Telangiectasia Mutated gene; associated with extensive lymphadenopathy and aggressive progression.
  • Trisomy 12 ($+12$): Intermediate-to-adverse risk; associated with atypical morphology and higher CD20 expression.
  • Unmutated $IGHV$: $<2%$ somatic hypermutation (germline configuration), indicating a pre-germinal center naive B-cell origin; aggressive clinical course.
  • Flow Cytometric Surrogates: High expression of CD38 ($\ge 30%$) and ZAP-70 ($\ge 20%$) correlates closely with unmutated $IGHV$ and poor prognosis.

Major Complications of CLL

1. Autoimmune Cytopenias: 5–10% of CLL patients develop secondary autoimmune complications mediated by polyclonal IgG autoantibodies produced by non-neoplastic B-cells stimulated by dysregulated T-helper networks: Warm Autoimmune Hemolytic Anemia (WAIHA, DAT/Coombs positive) and Immune Thrombocytopenia (ITP).
2. Hypogammaglobulinemia: Progressive reduction in normal polyclonal immunoglobulin synthesis (IgG, IgA, IgM) occurs in $>85%$ of advanced patients, leading to severe, recurrent bacterial infections (especially encapsulated organisms like S. pneumoniae and H. influenzae), which represent the leading cause of death.
3. Richter Transformation (Richter's Syndrome): Sudden transformation (in 5–10% of patients) of indolent CLL into an aggressive, high-grade Diffuse Large B-Cell Lymphoma (DLBCL) or rarely Hodgkin lymphoma. Manifests clinically as rapid asymmetrical lymph node enlargement, worsening B-symptoms (fever, drenching sweats, weight loss), markedly elevated serum LDH, and a median survival $<6\text{--}12$ months.

---

2. Hairy Cell Leukemia (HCL)

Hairy Cell Leukemia is an uncommon, indolent mature B-cell neoplasm accounting for ~2% of all lymphoid leukemias. It predominantly affects middle-aged to elderly males (median age 55; male-to-female ratio 4:1 to 5:1).

                     HAIRY CELL LEUKEMIA PATHOLOGY
                                   │
     ┌─────────────────────────────┼─────────────────────────────┐
     ▼                             ▼                             ▼
[ CLINICAL TRIAD ]        [ MORPHOLOGY & MARROW ]       [ IMMUNOPHENOTYPE & GENETICS ]
• Massive Splenomegaly    • Circumferential "Hair-like" • CD19+, CD20+ (Bright)
• Pancytopenia with         Cytoplasmic Projections     • CD11c+, CD25+, CD103+, CD123+
  Severe Monocytopenia    • Spongy, Oval Chromatin      • Annexin A1+ (Pathognomonic)
• Absence of Peripheral   • Bone Marrow Reticulin       • TRAP Positive
  Lymphadenopathy           Fibrosis ("Dry Tap")        • BRAF V600E Mutation (>95%)

Clinical Presentation & Smear Morphology

• Clinical Hallmarks: Massive splenomegaly (extending into the pelvis) in the absence of peripheral lymphadenopathy, accompanied by pancytopenia with profound monocytopenia (absolute monocyte count often $<0.05 \times 10^9/\text{L}$, predisposing to opportunistic atypical mycobacterial infections).
• Cytology: Leukemic cells are medium-to-large ($15\text{--}20\ \mu\text{m}$) mononuclear cells with abundant pale, grey-blue cytoplasm featuring fine, delicate, circumferential hair-like or serrated cytoplasmic projections. Nuclei are oval, reniform (kidney-shaped), or indented with a distinctive "spongy" or ground-glass chromatin and inconspicuous nucleoli.
• Bone Marrow Findings: Aspiration yields a "dry tap" due to diffuse marrow reticulin fibrosis produced by hairy cells. Core biopsy displays a characteristic "fried-egg" appearance—cells are widely separated by clear cytoplasmic halos around uniform round/oval nuclei with distinct cell borders.

Cytochemistry, Genetics & Immunophenotype

• Tartrate-Resistant Acid Phosphatase (TRAP) Positive: Incubation of smear preparations with $L-(+)$-tartaric acid inhibits standard lysosomal acid phosphatase isoenzymes 0, 1, 2, 3, and 4, but fails to inhibit isoenzyme 5 (tartrate-resistant) present abundantly in hairy cells, yielding intense red granular cytoplasmic staining.
• $BRAF$ V600E Somatic Mutation: Present in $>95\text{--}100%$ of classical HCL cases. A point mutation (T1799A) in exon 15 of the BRAF proto-oncogene results in a valine-to-glutamic acid substitution at residue 600, causing constitutive phosphorylation and activation of the MEK-ERK MAPK pathway.
• Diagnostic Immunophenotype: Strong expression of pan-B-cell markers (CD19+, CD20+ bright, sIg+ bright) co-expressed with the pathognomonic tetrad: CD11c+ (bright), CD25+ (bright), CD103+ (bright), and CD123+, along with Annexin A1+ (the most specific marker distinguishing classical HCL from variant HCL). CD5, CD10, and CD23 are typically negative.
• Therapy: Highly sensitive to purine nucleoside analogues (Cladribine / 2-CdA or Pentostatin), achieving durable complete remissions in $>85%$ of patients; BRAF inhibitors (Vemurafenib) for refractory disease.

---

3. Other Key Indolent B-Cell Lymphomas

A. Follicular Lymphoma (FL)

• Pathophysiology: Originates from germinal center B-cells (centrocytes and centroblasts). Characterized cytogenetically by the reciprocal translocation $\text{t}(14;18)(\text{q}32;\text{q}21)$, which translocates the $BCL2$ proto-oncogene on chromosome 18q21 to the $IGH$ locus on 14q32. This causes constitutive overexpression of the BCL2 anti-apoptotic protein, suppressing normal programmed cell death in the germinal center.
• Morphology: Displays a mixture of centrocytes (small-to-medium cleaved cells with irregular, notched, indented "buttock" nuclei) and centroblasts (large non-cleaved cells with vesicular chromatin and multiple peripheral nucleoli).
• Immunophenotype: CD19+, CD20+ (bright), CD10+, BCL6+, BCL2+, surface Ig+ (bright); CD5 NEGATIVE, CD23 negative/variable, and CD43 NEGATIVE.

B. Mantle Cell Lymphoma (MCL)

• Pathophysiology: Originates from pre-germinal center naive B-cells in the mantle zone. Defined by the translocation $\text{t}(11;14)(\text{q}13;\text{q}32)$, which juxtaposes the $CCND1$ ($BCL1$) gene on 11q13 to the $IGH$ enhancer on 14q32. This drives continuous nuclear overexpression of Cyclin D1, forcing cells through the G1/S cell cycle checkpoint.
• Morphology: Monomorphic population of small-to-medium lymphocytes with irregular, indented nuclear contours and condensed chromatin.
• Immunophenotype & Critical Differentiation from CLL: CD19+, CD20+ (bright), CD5+, CD43+, and Cyclin D1+ (nuclear), along with SOX11+. Unlike CLL, Mantle Cell Lymphoma is CD23 NEGATIVE, CD200 NEGATIVE, and expresses bright surface immunoglobulin.

C. Marginal Zone Lymphoma (MZL) / MALT Lymphoma

• Pathophysiology: Originates from memory B-cells in the marginal zone of lymphoid follicles. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) arises in tissues chronically inflamed by autoimmune disease or infection: $Helicobacter\ pylori$ gastritis, Hashimoto thyroiditis, and Sjögren syndrome (salivary glands).
• Immunophenotype: CD19+, CD20+, CD79a+, CD43+; CD5 NEGATIVE, CD10 NEGATIVE, CD23 NEGATIVE, and Cyclin D1 NEGATIVE.

---

4. Flow Cytometry & Cytogenetic Differential Matrix of Mature B-Cell Disorders